Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 02 08 2018
accepted: 09 10 2018
pubmed: 10 11 2018
medline: 14 6 2019
entrez: 10 11 2018
Statut: ppublish

Résumé

This study aimed to investigate the effects of desumoylating isopeptidase 2 (DESI2) on tumor cell proliferation, apoptosis and invasion of pancreatic cancer, and to assess the signaling pathway involved. Overexpression and silence of DESI2 were designed and the experiments were divided into 5 groups: a normal control group, an interference control group (shRNA-NC); an interference group (sh-DESI2); an overexpression control group (NC), an overexpression group (DESI2). Quantitative real time polymerase chain reaction (qRT-PCR) was used to screen the appropriate interference sequence. The silencing and overexpression of DESI2 were confirmed by qRT-PCR and western blotting. Cell cycling, apoptosis, invasion, and the expression of phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway and caspase 3 were measured. Overexpression and silence of DESI2 were successfully designed in two pancreatic cancer cells, and the interference effect of sh-DESI2-3 showed the best silencing effects. The biological activities of DESI2 were detected in both ASPC-1 and PANCE-1 cells. Our results showed that cell proliferation was significantly increased in the sh-DESI2 group, while decreased in DESI2 group compared with the control group in both cell lines. In ASPC-1 cells, the events in G1 phase decreased and in S phase increased obviously in the sh-DESI2 group, compared with control group. An opposite result was found when DESI2 was overexpressed. In PANCE-1 cells, the events in G2 phase were higher in the sh-DESI2 group, while in the DESI2 group was significantly lower than that in control group. In ASPC-1 and PANCE-1 cells, sh-DESI2 group showed decreased apoptosis, increased cell invasion and increased expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and decreased caspase 3 expression compared with the control group, while overexpression of DESI2 leaded to increased apoptosis, decreased cell invasion and reduced expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and increased expression of caspase 3. DESI2 regulates the proliferation and apoptosis of pancreatic cancer cells through PI3K/AKT/mTOR signaling pathway.

Identifiants

pubmed: 30411297
doi: 10.1007/s12253-018-0487-4
pii: 10.1007/s12253-018-0487-4
doi:

Substances chimiques

MTOR protein, human EC 2.7.1.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1
Carbon-Nitrogen Lyases EC 4.3.-
DESI2 protein, human EC 4.3.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

635-646

Références

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903
pubmed: 12477932
Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91
pubmed: 15028555
Cell Biol Int. 2009 Mar;33(3):276-82
pubmed: 19101642
Biochimie. 2009 Apr;91(4):502-7
pubmed: 19133312
Cancer Chemother Pharmacol. 2009 Dec;65(1):13-25
pubmed: 19387645
Cancer Sci. 2009 Sep;100(9):1757-66
pubmed: 19575751
J Biomed Biotechnol. 2010;2010:134764
pubmed: 20454583
J Mol Signal. 2010 Jul 19;5:10
pubmed: 20642839
Oncol Rep. 2011 Sep;26(3):703-10
pubmed: 21667029
Clin Cancer Res. 2012 Apr 15;18(8):2316-25
pubmed: 22261800
Neurochem Int. 2012 Mar;60(4):400-8
pubmed: 22265823
J Clin Oncol. 2012 Mar 10;30(8):777-82
pubmed: 22271473
Oncol Rep. 2012 Aug;28(2):501-10
pubmed: 22641480
Apoptosis. 2013 Apr;18(4):467-79
pubmed: 23322088
Virchows Arch. 2013 Apr;462(4):429-36
pubmed: 23443941
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Br J Cancer. 2014 Aug 26;111(5):817-22
pubmed: 24755884
Pathol Oncol Res. 2015 Apr;21(2):267-72
pubmed: 25079376
J Neurosci. 2015 Jan 14;35(2):621-33
pubmed: 25589756
Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):623-34
pubmed: 25743573
J Biol Chem. 2015 Jun 12;290(24):14927-44
pubmed: 25918161
Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1317-26
pubmed: 26399781
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
Oncotarget. 2016 Feb 23;7(8):9135-49
pubmed: 26824320
Oncotarget. 2016 Feb 23;7(8):9586-99
pubmed: 26840020
Cell Death Dis. 2016 Feb 04;7:e2087
pubmed: 26844701
Res Vet Sci. 2016 Apr;105:124-33
pubmed: 27033920
Avicenna J Med Biotechnol. 2016 Apr-Jun;8(2):75-83
pubmed: 27141266
Mol Cell Oncol. 2014 Oct 29;1(3):e963447
pubmed: 27308344
Oncotarget. 2016 Nov 22;7(47):77916-77925
pubmed: 27788491
Mol Med Rep. 2017 May;15(5):3259-3263
pubmed: 28339041
J Exp Clin Cancer Res. 2017 Sep 11;36(1):124
pubmed: 28893319
Oncotarget. 2017 May 5;8(34):56281-56295
pubmed: 28915590
Oncotarget. 2017 Sep 27;8(50):87997-88007
pubmed: 29152136

Auteurs

Xi Ou (X)

Department of Hepatopancreatobiliary Surgery, Peking University Shenzhen Hospital, Lian Hua Road 1120, Shenzhen, 518036, China.

Guang-Tao Zhang (GT)

Department of Hepatopancreatobiliary Surgery, Peking University Shenzhen Hospital, Lian Hua Road 1120, Shenzhen, 518036, China.

Zhe Xu (Z)

The Third Ward of Liver Disease, The Third People's Hospital of Shenzhen, Shenzhen, 518112, China.

Jing-Sen Chen (JS)

Breast Department, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, 518028, China.

Yong Xie (Y)

Department of Hepatopancreatobiliary Surgery, Peking University Shenzhen Hospital, Lian Hua Road 1120, Shenzhen, 518036, China.

Ji-Kui Liu (JK)

Department of Hepatopancreatobiliary Surgery, Peking University Shenzhen Hospital, Lian Hua Road 1120, Shenzhen, 518036, China. liu89201@sina.com.

Xiao-Ping Liu (XP)

Department of Hepatopancreatobiliary Surgery, Peking University Shenzhen Hospital, Lian Hua Road 1120, Shenzhen, 518036, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH